Literature DB >> 27177728

Complications of Cushing's syndrome: state of the art.

Rosario Pivonello1, Andrea M Isidori2, Maria Cristina De Martino3, John Newell-Price4, Beverly M K Biller5, Annamaria Colao3.   

Abstract

Cushing's syndrome is a serious endocrine disease caused by chronic, autonomous, and excessive secretion of cortisol. The syndrome is associated with increased mortality and impaired quality of life because of the occurrence of comorbidities. These clinical complications include metabolic syndrome, consisting of systemic arterial hypertension, visceral obesity, impairment of glucose metabolism, and dyslipidaemia; musculoskeletal disorders, such as myopathy, osteoporosis, and skeletal fractures; neuropsychiatric disorders, such as impairment of cognitive function, depression, or mania; impairment of reproductive and sexual function; and dermatological manifestations, mainly represented by acne, hirsutism, and alopecia. Hypertension in patients with Cushing's syndrome has a multifactorial pathogenesis and contributes to the increased risk for myocardial infarction, cardiac failure, or stroke, which are the most common causes of death; risks of these outcomes are exacerbated by a prothrombotic diathesis and hypokalaemia. Neuropsychiatric disorders can be responsible for suicide. Immune disorders are common; immunosuppression during active disease causes susceptibility to infections, possibly complicated by sepsis, an important cause of death, whereas immune rebound after disease remission can exacerbate underlying autoimmune diseases. Prompt treatment of cortisol excess and specific treatments of comorbidities are crucial to prevent serious clinical complications and reduce the mortality associated with Cushing's syndrome.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 27177728     DOI: 10.1016/S2213-8587(16)00086-3

Source DB:  PubMed          Journal:  Lancet Diabetes Endocrinol        ISSN: 2213-8587            Impact factor:   32.069


  110 in total

Review 1.  Medical Treatment of Cushing's Disease: An Overview of the Current and Recent Clinical Trials.

Authors:  Rosario Pivonello; Rosario Ferrigno; Maria Cristina De Martino; Chiara Simeoli; Nicola Di Paola; Claudia Pivonello; Livia Barba; Mariarosaria Negri; Cristina De Angelis; Annamaria Colao
Journal:  Front Endocrinol (Lausanne)       Date:  2020-12-08       Impact factor: 5.555

Review 2.  A Clinical Perspective of Sleep and Andrological Health: Assessment, Treatment Considerations, and Future Research.

Authors:  Peter Y Liu
Journal:  J Clin Endocrinol Metab       Date:  2019-10-01       Impact factor: 5.958

Review 3.  Glucocorticoids in pregnancy.

Authors:  Riccardo Pofi; Jeremy W Tomlinson
Journal:  Obstet Med       Date:  2019-06-09

4.  Laparoscopic bilateral anterior transperitoneal adrenalectomy: 24 years experience.

Authors:  Andrea Balla; Monica Ortenzi; Livia Palmieri; Diletta Corallino; Francesca Meoli; Pietro Ursi; Giulia Puliani; Emilia Sbardella; Andrea M Isidori; Mario Guerrieri; Silvia Quaresima; Alessandro M Paganini
Journal:  Surg Endosc       Date:  2019-01-23       Impact factor: 4.584

5.  Dimethoxy-etomidate: A Nonhypnotic Etomidate Analog that Potently Inhibits Steroidogenesis.

Authors:  Megan McGrath; Celena Ma; Douglas E Raines
Journal:  J Pharmacol Exp Ther       Date:  2017-12-04       Impact factor: 4.030

Review 6.  Functional imaging in ectopic Cushing syndrome.

Authors:  Seda Grigoryan; Anca M Avram; Adina F Turcu
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2020-06       Impact factor: 3.243

7.  Population Pharmacokinetics of Subcutaneous Pasireotide in Healthy Volunteers and Cushing's Disease Patients.

Authors:  Jerry Nedelman; Roland Fisch; Ke Hu; Ines Paule; Jocelyn Zhou
Journal:  Clin Pharmacokinet       Date:  2018-07       Impact factor: 6.447

8.  Role of Mineralocorticoid Receptor in Adipogenesis and Obesity in Male Mice.

Authors:  Daniel Ferguson; Irina Hutson; Eric Tycksen; Terri A Pietka; Kevin Bauerle; Charles A Harris
Journal:  Endocrinology       Date:  2020-02-01       Impact factor: 4.736

9.  High bone marrow fat in patients with Cushing's syndrome and vertebral fractures.

Authors:  Francesco Ferraù; Salvatore Giovinazzo; Erika Messina; Agostino Tessitore; Sergio Vinci; Gherardo Mazziotti; Andrea Lania; Francesca Granata; Salvatore Cannavò
Journal:  Endocrine       Date:  2019-08-02       Impact factor: 3.633

10.  Pasireotide treatment reduces cardiometabolic risk in Cushing's disease patients: an Italian, multicenter study.

Authors:  A Albani; F Ferraù; A Ciresi; R Pivonello; C Scaroni; D Iacuaniello; M Zilio; V Guarnotta; A Alibrandi; E Messina; M Boscaro; C Giordano; A Colao; S Cannavo
Journal:  Endocrine       Date:  2018-01-30       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.